We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

News

News

Agendia Joins the Personalized Medicine Coalition

The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling.
News

DxS K-RAS Mutation Detection Kit Used To Assess Tumour Mutation Status Prior to Treatment with Amgen’s Vectibix™

Amgen has selected Kit to analyse patient samples from the pivotal“408” study examining Vectibix versus best supportive care in patients with metastatic colorectal cancer.
News

Molecular Sensing to Commercialize New Biosensor Technology Exclusively Licensed from Vanderbilt University

MSI plans to produce biosensor products for research, diagnostic, biodefense and pharmacogenomic applications.
News

Moffitt Selects Microsoft's Azyxxi to Help Drive Personalized Cancer Treatment

Software to save years in research that aligns patients and treatments.
News

Oxford Genome Sciences Announces New Therapeutic Antibody Deal with Medarex

New agreement to drive the development of OGeS’ own pipeline of antibodies in cancer.
News

FDA Clears Genetic Lab Test for Warfarin Sensitivity

Research has shown that some of the unexpected response to warfarin depends on variants of two genes, CYP2C9 and VKORC1.
News

bioMerieux and Ipsen Sign Theragnostics Agreement to Develop Companion Test for new Breast Cancer Treatment

bioMerieux will develop a companion test for a new breast cancer drug undergoing clinical evaluation by Ipsen.
News

Med BioGene Welcomes Renowned Expert to Lymphoma Collaboration

Med BioGene Inc. has welcomed Sandeep S. Dave, M.D. of Duke University to its lymphoma collaboration.
News

SRI International and Pentax Corporation Develop Biomarkers for Oncology Diagnostics

The ultimate goal of the collaboration is to develop medical diagnostic tools for therapeutic intervention in the treatment of cancer.
News

DxS Signs a License with DiagnoCure for its Scorpions® Technology

DiagnoCure will gain access to Scorpions for the development of their GCC-based molecular test for colorectal cancer.
Advertisement